Kiran Nistala
CIK 2003539 · View on SEC EDGAR ↗
First SEC filing: Jan. 26, 2024 · Latest: Jan. 26, 2024
On this page
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| April 22, 2024 | ZURA | P | 3,195 | $3.13 | $10,000 | 3,195 Direct | — | Acquired | 82.7% (price as of 2026-08-20) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| June 18, 2024 | ZURA | Employee Share Option (Right to Buy) | Class A Ordinary Shares (285,000) | $3.38 | June 18, 2034 | 285,000 | Acquired |
| Jan. 24, 2024 | ZURA | Stock options | Class A Ordinary Shares (350,000) | $3.98 | Jan. 24, 2034 | 350,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
ZURA
Chief Medical Officer and Head of Development| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2024 | $409,600 | $177,357 | — | $1,933,564 | — | — | $10,454 | $2,530,975 |
| 2023 | $14,769 | — | — | — | — | — | — | $14,769 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.